Director Kevin Rakin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Director kevin rakin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Director Kevin Rakin Today - Breaking & Trending Today

Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Announce Quarterly Sales of $700,000.00

Wall Street brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to report sales of $700,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $680,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of […] ....

Kevin Rakin , Oramed Pharmaceuticals Inc , Securities Exchange Commission , Zacks Investment Research , Oramed Pharmaceuticals , Invesco Ltd , Oramed Pharmaceuticals Get Rating , Cantor Fitzgerald , Moors Cabot Inc , Millennium Management , Wall Street , Get Rating , Oramed Pharmaceutical , Investment Research , Director Kevin Rakin , Exchange Commission , Capital Management , Pharmaceuticals Inc , Nasdaq Ormp ,

Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by StockNews.com to "Hold"

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. A number of other research firms have also recently commented on ORMP. Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals in a research report on Friday, February 18th. They set an “overweight” […] ....

Hong Kong , Zurcher Kantonalbank Zurich Cantonalbank , Kevin Rakin , Oramed Pharmaceuticals Inc , Wells Fargo Company , Cantor Fitzgerald , Oramed Pharmaceuticals Company Profile Get Rating , Oramed Pharmaceuticals , Hong Kong Ltd , Royal Bank , Get Rating , Director Kevin Rakin , Kong Ltd , Pharmaceuticals Company Profile , Pharmaceuticals Inc , Nasdaq Ormp , Stocknews Com ,

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Given Consensus Recommendation of "Buy" by Brokerages

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) has earned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among […] ....

Hong Kong , Kevin Rakin , Oramed Pharmaceuticals Inc , Securities Exchange Commission , Oramed Pharmaceuticals , Oramed Pharmaceuticals Get Rating , Wells Fargo Company , Cantor Fitzgerald , Close Asset Management Ltd , Royal Bank , Hong Kong Ltd , Get Rating , Marketbeat Ratings , Director Kevin Rakin , Exchange Commission , Kong Ltd , Asset Management Ltd , Wells Fargo , Pharmaceuticals Inc , Nasdaq Ormp ,

Analysts Anticipate Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) to Post -$0.19 Earnings Per Share

Equities analysts expect that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.15). Oramed Pharmaceuticals posted earnings […] ....

Kevin Rakin , Oramed Pharmaceuticals Inc , Geode Capital Management , Securities Exchange Commission , Zacks Investment Research , Blackrock Inc , Oramed Pharmaceuticals , Invesco Ltd , Oramed Pharmaceuticals Get Rating , Morgan Jesss Co , Cantor Fitzgerald , Get Rating , Oramed Pharmaceutical , Director Kevin Rakin , Exchange Commission , Capital Management , Pharmaceuticals Inc , Nasdaq Ormp ,

Analysts Expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Post Quarterly Sales of $700,000.00

Brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to announce sales of $700,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of […] ....

United States , Thomson Reuter , Kevin Rakin , Oramed Pharmaceuticals Inc , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Oramed Pharmaceuticals , America Corp , Invesco Ltd , Oramed Pharmaceuticals Get Rating , Wells Fargo Company , Cantor Fitzgerald , Royal Bank , Get Rating , Zacks Investment , Oramed Pharmaceutical , Investment Research , Director Kevin Rakin , Exchange Commission , Wells Fargo , Nasdaq Ormp ,